medigraphic.com
ISSN 1560-4381 (Print)

2016, Number 1

<< Back Next >>

Correo Científico Médico 2016; 20 (1)

Presentation of an adolescent with gigantism

Romero PI, Tamayo RW, Odou CJR

Language: Spanish
References: 7
Page: 182-188
PDF size: 109.90 Kb.


ABSTRACT

Gigantism, a hormonal disease caused by the excessive secretion of the growth hormone of the anterior pituitary gland, while the epiphysis of the bones is not still closed, it causes an overgrowth body gain height. An 18- year-old male teenager suffering from pain in arms and legs, from his early years presented an overgrowth of all his body, in the physical exam and 2.17 meters of height. He also presented a slow development in his sexual organs. The symptoms found, together with some other test showed a diagnosis of gigantism associated with mild hypogonadism and thyroid hypofuntion. To know the growth hormone, a computer axial tomography and a magnetic resonance were needed in order to determine an exact diagnosis but it was postponed because of for financial reasons.


REFERENCES

  1. Gläsker S, Vortmeyer AO, Lafferty AR, Hofman LP, Jie Li, Weil RJ, et al. Hereditary Pituitary Hyperplasia with Infantile Gigantism. J Clin Endocrinol Metab. 2011[citado 18 feb 2014]; 96(12).Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232621

  2. Bhattacharjee R, Ajitesh R, Soumik G, Chitra S, Partha PC, Sujoy G, et al. Pituitary Gigantism: A Case Report. Ind J Endocrinol Metabol. 2014 [citado 18 feb 2014]; 16(2). Disponible en: http://www.ijem.in/temp/IndianJEndocrMetab168285-3549374_095133.pdf.

  3. Xian ling W, ing tao D, Zhao hui L, Wen wen Z, Jian ming B, Du J, et al. Spontaneous remission of acromegaly or gigantism due to subclinical apoplexy of pituitary growth hormone adenoma. Chin Med J. 2011[citado 18 feb 2014]; 124(22): Disponible en: http://www.cmj.org/ch/reader/view_abstract.aspx?volume=124&issue=22&start_page=3820.

  4. Wilches VC, Gallo A, Daza Cajas GF, Tafur AM, Rivero Rapalino M, Triana G. El miembro asimétrico (gigantismo): Aproximación diagnóstica. Rev Colomb Radiol. 2009 [citado 18 feb 2014]; 20(4).Disponible en: https://www.acronline.org/LinkClick.aspx?fileticket=4eTIU0Sf3bU%3d&tabid=113

  5. Shimatsu A, Teramoto A, Hizuka N, Kitai K, Ramis J, Chihara K. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism. Endocr J. 2013 [citado 18 feb 2014]; 60(5). Disponible en: https://www.jstage.jst.go.jp/article/endocrj/60/5/60_EJ12-0417/_article

  6. Corrado R, Francheri Wilson A, Tello C, Noel M, Galaretto E, Bersusky E. Sotos syndrome and scoliosis surgical treatment: a 10-year follow-up. Eur Spine J. 2011. [citado 18 feb 2014]; 20(supl 2). Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111518/pdf/586_2010_Article_1685.pdf.

  7. Goldenberg N, Racine MS, Thomas P, Degnan B, Chandler W, Barkan A. Treatment of Pituitary Gigantism with the Growth Hormone Receptor Antagonist Pegvisomant. J Clin Endocrinol Metab. 2008 [citado 18 feb 2014]; 93(8).Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515082/?report=classic




2020     |     www.medigraphic.com